75
Participants
Start Date
September 12, 2018
Primary Completion Date
January 23, 2025
Study Completion Date
January 23, 2025
Domvanalimab
Domvanalimabis a fully human immunoglobulin G1 (IgG1) monoclonal antibody targeting human TIGIT
Zimberelimab
Zimbererlimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1
The Kinghorn Cancer Centre - St Vincent Public Hospital, Darlinghurst
Tweed Hospital, Tweed Heads
Olivia Newton-John Cancer Research Institute-Austin Hostipal, Heidelberg
Icon Cancer Care Brisbane, South Brisbane
Carolina BioOncology Institute, Huntersville
Affinity Health-Hope and Healing Cancer Services, LLC, Hinsdale
MD Anderson Cancer Center, Houston
START, San Antonio
The Angeles Clinic and Research Institute, Los Angeles
Medical Oncology Associates, PS (dba Summit Cancer Centers), Spokane
Lead Sponsor
Collaborators (1)
Gilead Sciences
INDUSTRY
Arcus Biosciences, Inc.
INDUSTRY